2026 HFM CME Symposium - Overcoming Challenges in Transthyretin Cardiac Amyloidosis

HAZLET, N.J. - EntSun -- Historically, ATTR-CM was considered a rare disease; however, it is now recognized as a more common cause of heart failure (HF) than previously thought. Despite recent attention to ATTR-CM, the condition is significantly underdiagnosed. Timely diagnosis is crucial, as it has the potential to reduce mortality and HF hospitalization when treated with targeted therapies. In this symposium, ATTRCM experts (symposium chair Dr. Mathew Maurer, faculty members Dr. Jan Griffin and Dr. Frederick Ruberg), will provide attendees with best practices for evaluating, diagnosing, and treating patients with ATTR-CM.

Click here for more information

CHAIR

Mathew Maurer, MD

More on EntSun News

• Two Attorneys at The Stanley Law Group Named to 2026 South Carolina Super Lawyers List
• MetroLagoons extends partnership with Velocity Custom Golf Cars
• IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
• The Explorer Shaped Guitar Still a Symbol of Heavy Music with New Releases
• Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services

Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Jan Griffin, MD
Associate Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina

Frederick Ruberg, MD
Thomas J. Ryan Professor of Cardiovascular Medicine
Chief, Cardiovascular Medicine
Professor of Radiology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, Massachusetts

Educational Objectives

- Recognize the cardiac and extracardiac red flags which raise suspicion for ATTR-CM.
- Describe the diagnostic testing components to quickly and accurately diagnose ATTR-CM.
- Summarize current recommendations for use of HF GDMT in ATTR-CM patients and the evolving evidence for Silencers and Stabilizers for ATTR-CM.
- Identify the recommended parameters for monitoring disease progression in ATTR-CM.

More on EntSun News

• America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
• Data Tiles Introduces the Decision-Driven Enterprise to North America
• Attorney-Turned-Designer Chalon Clark Joins HGTV's 'Renovation Resort Showdown'
• Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
• Las Vegas Filmmaker Trina Colon's Debut Feature, " Sunny Yard," Wins Best In Fest

Target Audience
This program is intended for clinicians who manage patients with heart failure.

Educational Grant
Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc. and BridgeBio.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Voxmedia, LLC designates this live activity for a maximum
of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a
certifi cate of completion as AANP accepts AMA PRA Category 1 Credits™
through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts
AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.